Svalbard and Jan Mayen

Reimbursed Care Access

Svalbard and Jan Mayen are under Norwegian criminal and pharmaceutical law, so the legal and reimbursement landscape for psychedelics follows Norway. Current Norwegian policy permits licensed medical use of ketamine (including recent national reimbursement arrangements for off‑label IV ketamine for treatment‑resistant depression in public specialist services) and authorises esketamine (Spravato) as an on‑label medicine although it has limited public financing; all classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5‑MeO‑DMT, ibogaine, ayahuasca, 2C‑X) remain tightly controlled with no routine medical reimbursement outside approved clinical research. [https://sherloc.unodc.org/cld/en/legislation/nor/penal_code/part_i_-_chapter_1/sections_47/sections_47.html|Norwegian Penal Code / UNODC]